A

Albany Med Health System

Academic medical center delivering care, research

Executive Assistant - System General Counsel

Full-TimePosted on 10/20/2026
$77.1k - $119.5k
Senior
Bachelor's
Albany, NY, USA
In Person
Administrative & Executive AssistanceExecutive Support

About the job

Requirements
  • A bachelor's degree is required.
  • At least 5 years of experience supporting senior legal executives is required.
  • Prior experience in a healthcare or hospital environment is preferred.
  • Experience supporting complex organizations with multiple stakeholders is preferred.
  • A strong understanding of legal department operations and the healthcare environment is preferred.
  • Strong organizational and prioritization skills in a high-demand, fast-paced setting are required.
  • Advanced written and verbal communication skills, including executive-level correspondence, are required.
  • A high level of discretion, judgment, and professionalism is required.
  • The ability to anticipate needs and proactively resolve issues is required.
  • Strong relationship-building skills across clinical and administrative teams are required.
  • Proficiency in Microsoft Office Suite and collaboration platforms is required.
  • The ability to manage multiple priorities with accuracy and attention to detail is required.
  • Demonstrated ability to support strategic initiatives and project coordination is required.
Responsibilities
  • Provide confidential executive administrative support to the System General Counsel and other members of the Legal Department, exercising sound judgment, discretion, and professionalism in handling sensitive legal, business, and personnel matters.
  • Manage a complex calendar, prioritize meeting requests, and coordinate appointments, travel, and scheduling across system entities.
  • Serve as a primary administrative point of contact for the Office of the General Counsel, interacting professionally with executive leaders, Board members, physicians, employees, outside counsel, and external organizations.
  • Coordinate meetings, including preparing agendas and materials, recording action items as requested, and tracking follow-up assignments.
  • Receive and route legal inquiries, correspondence, and time-sensitive documents to the appropriate attorney or department; promptly escalate matters requiring immediate attention.
  • Organize and maintain electronic and physical files in accordance with departmental procedures, confidentiality requirements, records retention schedules, and legal hold instructions.
  • Support Board and committee activities as assigned, including coordinating legal review of materials and securely distributing confidential documents.
  • Coordinate administrative activities with outside counsel, including processing engagement documentation, tracking invoices, and supporting legal expense reporting and budget monitoring.
  • Assist with the administrative coordination of subpoenas, litigation, investigations, and regulatory matters under attorney direction, including scheduling and collecting requested materials.
  • Process expense reports, purchase requests, and other departmental transactions accurately and promptly.
  • Improve administrative workflows and use technology to strengthen document management, scheduling, communication, and departmental efficiency.
  • Collaborate with executive assistants and administrative teams across the health system to coordinate priorities and support effective system operations.
  • Exercise independent judgment within delegated administrative authority and refer matters requiring legal interpretation or advice to the appropriate attorney.

About the company

A

Albany Med Health System

View

Albany Medical Center is a major health system in northeastern New York that combines a 766-bed hospital, Albany Medical College, and a large physician practice. It delivers comprehensive clinical care—emergency and trauma services, pediatric care, ICUs, organ transplants—and offers education and biomedical research through its college and research enterprise. The system operates the region’s busiest emergency and trauma center and runs a large medical education and training program, graduating hundreds of doctors and allied health professionals each year. Its model links patient care, education, and research under one not-for-profit, regionally governed umbrella, Albany Med Health System. The goal is to provide high-quality patient care while expanding medical knowledge and training to improve regional health outcomes.

Company Size

5,001-10,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Albany, New York

Founded

N/A

Get referred to Albany Med Health System

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The $25 million Albany Medical Center ED expansion targets completion by end-2026.
  • Albany Med pursued Ellis Medicine affiliation in July 2026, expanding local market control.
  • System news in 2026 highlights robotic Whipple, bladder cancer care, and cardiovascular recognition.

What critics are saying

  • Albany Med laid off 37 staff in January 2026 after a $66 million loss.
  • Columbia Memorial's 192-to-25 bed plan triggered union backlash and state review in 2026.
  • The CDPHP payment dispute threatened roughly $50 million and exposed revenue concentration risk.

What makes Albany Med Health System unique

  • Albany Med runs a regional system spanning Albany, Saratoga, Glens Falls, and Columbia.
  • Its academic center plus community hospitals create referral gravity across upstate New York.
  • The 2025–2026 emergency department expansions signal capital access and operational scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance

Company News

EurekAlert!
Oct 2nd, 2026
Salk scientist Tony Hunter receives 2026 Albany Prize.

Salk scientist Tony Hunter receives 2026 Albany Prize. Salk Institute LA JOLLA (October 2, 2026) - Tony Hunter, PhD, American Cancer Society Professor and Renato Dulbecco Chair at Salk, has been awarded the 2026 Albany Prize in Medicine and Biomedical Research - one of the largest and most prestigious science awards in the world. Albany Medical College chose Hunter and UC Los Angeles oncologist Dennis Slamon, MD, PhD, to receive this year's prize in honor of their cancer biology discoveries that together have saved millions of lives worldwide. Hunter is recognized for his identification of a molecular switch known as tyrosine phosphorylation, which has been targeted to create more than 100 cancer drugs. "Tony's dedication to curiosity-driven research has made him an irreplaceable asset at Salk and in science at large," says Salk President Gerald Joyce, MD, PhD. "His commitment to foundational discovery has transformed cancer biology and treatment, and we look forward to celebrating this honor with him." About the Albany Prize The Albany Prize has been awarded each year since 2001 in recognition of exceptional work in medicine and biomedical research. It was established by the late Morris "Marty" Silverman, who had a vision to recognize scientists for "bench to bedside" work that has improved the lives of patients across the country and around the globe. The award comes with a $500,000 prize thanks to a $50 million gift commitment from the Marty and Dorothy Silverman Foundation to Albany Medical Center. Their gift ensures the award can be given for 100 years, continuing its prestigious reputation near the rank of the Nobel Prize. Other distinguished scientists who have received the Albany Prize include former National Institute of Allergy and Infectious Disease director Anthony Fauci, MD; CRISPR pioneers and Nobel Laureates Emmanuelle Charpentier, PhD, and Jennifer Doudna, PhD; and mRNA vaccine pioneers and Nobel Laureates Katalin Karikó, PhD, and Drew Weissman, MD, PhD, among many others. Tony Hunter's lifesaving discovery and impactful career Hunter joins the illustrious ranks of past Albany Prize recipients because of his discovery of tyrosine phosphorylation, a serendipitous finding thanks to a tiny pH change. In 1979, while conducting an experiment to separate the amino acids in a viral protein, Hunter unknowingly used a buffer (a solution that helps control acidity) with a pH of 1.7 instead of 1.9. That small difference revealed tyrosine phosphorylation, a process in which an enzyme adds a phosphate group to the amino acid tyrosine in proteins. This remarkable discovery revealed a new class of enzymes called tyrosine kinases, which help regulate cell growth. After publishing the landmark study that introduced tyrosine kinases, Hunter went on to write and publish many additional papers on this new protein kinase family. Through his persistent curiosity, he came to understand that tyrosine kinases become overactive in many human cancers. This seminal discovery laid the groundwork for the development of the first tyrosine kinase inhibitor drugs to successfully treat cancers. Approved by the FDA in 2001, the revolutionary tyrosine kinase inhibitor imatinib (Gleevec) has transformed the treatment of chronic myelogenous leukemia from a terminal disease to a highly manageable condition. Today, more than 100 cancer drugs that block overactive tyrosine kinases exist thanks to Hunter's foundational work in identifying and characterizing tyrosine kinases. "A gratifying outcome of this set of experiments on a simple chicken tumor virus," Hunter wrote of his discovery in a 2015 Proceedings of the National Academy of Sciences perspective. 2025 marked Hunter's 50th year at the Salk Institute, where he is still an active researcher. In addition to his own collaborations and projects, he takes immense pride in training the future generation of cancer biologists and life sciences researchers. "When I'm teaching students, I say an awful lot has already been discovered, but an awful lot remains unknown. I'm sure that new biological principles will emerge that we can't even imagine right now," Hunter said in a 2023 feature in Inside Salk magazine. "I'm excited because there will always be new things to be discovered for as long as I'm alive." Tony Hunter's other awards and honors Hunter has received numerous accolades for his pivotal cancer research, including the Wolf Prize in Medicine, Gairdner Foundation International Award, Louisa Gross Horwitz Prize, National Cancer Institute Outstanding Investigator Award, American Association for Cancer Research Lifetime Achievement Award in Cancer Research, Sjöberg Prize for Cancer Research, Prince Mahidol Award, and Dr. Paul Janssen Award for Biomedical Research. Hunter has also been elected a fellow of the American Association for Cancer Research, Member of the American Philosophical Society; fellow of the Royal Society of London; Member of the National Academy of Sciences; fellow of the American Academy of Arts and Sciences; and Member of the National Academy of Medicine. More information About the Salk Institute for Biological Studies The Salk Institute is an independent, nonprofit research institute founded in 1960 by Jonas Salk, developer of the first safe and effective polio vaccine. The Institute's mission is to drive foundational, collaborative, risk-taking research that addresses society's most pressing challenges, including cancer, Alzheimer's disease, and crop resilience. This foundational science underpins all translational efforts, generating insights that enable new medicines and innovations worldwide. Learn more at www.salk.edu. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

The Business Journals
Sep 16th, 2026
Albany Med makes two more C-suite hires.

Albany Med makes two more C-suite hires. By Luke Nathan - Reporter, Albany Business Review Sep 16, 2026 Preview this article 1 min The execs are joining Albany Med from health systems in New York City and Colorado. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4